Home › Leucemia linfatica cronica › Missouri › Kansas City
Studi clinici su Leucemia linfatica cronica a Kansas City, MO
10 studi su Leucemia linfatica cronica cercano partecipanti presso sedi a Kansas City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
In reclutamentoFase 3
- MidAmerica Cancer Care, LLC ( Site 5426), Kansas City
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
In reclutamentoFase 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- e altri 1
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Kansas City Veterans Affairs Medical Center, Kansas City
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
In reclutamentoFase 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- e altri 2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
In reclutamentoFase 1/2
- The University of Kansas Cancer Center, Westwood · a 5 mi di distanza
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In reclutamentoFase 3
- The University of Kansas Cancer Center, Westwood · a 5 mi di distanza
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
In reclutamentoFase 3
- MidAmerica Cancer Care, LLC ( Site 0043), Kansas City
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
In reclutamentoFase 3
- Saint Lukes Hospital of Kansas City /ID# 267270, Kansas City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
In reclutamentoFase 1/2
- University of Kansas, Westwood · a 5 mi di distanza
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
In reclutamentoFase 2
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
Studi su Leucemia linfatica cronica in altre città
- Boston, MA31 studi
- Columbus, OH28 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- Rochester, MN18 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Chicago, IL14 studi
- Cincinnati, OH14 studi
Altri studi a Kansas City
- Cancro al seno34 studi
- Cancro del polmone non a piccole cellule31 studi
- Insufficienza cardiaca25 studi
- Cancro (tutti i tipi)21 studi
- Cancro ai polmoni19 studi
- Cancro colorettale16 studi
- Cancro metastatico15 studi
- Leucemia mieloide acuta15 studi
- Cancro alla prostata14 studi
- Cancro ovarico11 studi
- Obesità11 studi
- Diabete di tipo 211 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.